We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.
- Authors
Mutoh, Michihiro; Niho, Naoko; Wakabayashi, Keiji
- Abstract
Epidemiologically, a high-fat diet is associated with the risk of colon cancer. In addition, serum levels of triglycerides (TGs) and cholesterol have been demonstrated to be positively associated with colon carcinogenesis. We recently found that an age-dependent hyperlipidemic state (high serum TG levels) exists in Apc-deficient mice, an animal model for human familial adenomatous polyposis. The mRNA levels of lipoprotein lipase (LPL), which catalyzes TG hydrolysis, were shown to be downregulated in the liver and intestines of mice. Moreover, treatment with a peroxisome proliferator-activated receptor (PPAR) α agonist, bezafibrate, or a PPARγ agonist, pioglitazone, suppressed both hyperlipidemia and intestinal polyp formation in the mice, with induction of LPL mRNA. PPARα and PPARγ agonists are reported to exert anti-proliferative and pro-apoptotic effects in cancer cells. One compound that also increases LPL expression levels but does not possess PPAR agnostic activity is NO-1886. When given at 400 or 800 ppm in the diet, it suppresses both hyperlipidemia and intestinal polyp formation in Apc-deficient mice, with elevation of LPL mRNA. In conclusion, a decrease in serum lipid levels by increasing LPL activity may contribute to a reduction in intestinal polyp formation with Apc deficiency. PPARα and PPARγ agonists, as well as NO-1886, could be useful as chemopreventive agents for colon cancer.
- Subjects
COLON cancer; HYPERLIPIDEMIA; LIPOPROTEIN lipase; INTESTINAL polyps; CARCINOGENESIS
- Publication
Biological Chemistry, 2006, Vol 387, Issue 4, p381
- ISSN
1431-6730
- Publication type
Article
- DOI
10.1515/BC.2006.051